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Antiviral therapyAbstract Background: Hepatitis C virus (HCV) has been found to infect peripheral blood mono-
nuclear cells (PBMCs), using them as a reservoir, which might contribute to the development of
resistance to treatment.
Objectives: To study hepatitis virus C (HCV) RNA in peripheral blood mononuclear cells
(PBMCs) of patients with chronic HCV infection, and explore the relationship between the HCV
RNA in the PBMCs and response to interferon (IFN) therapy.
Methods: Twenty-ﬁve patients with chronic viral hepatitis C were included. The HCV RNA in
PBMCs and serum was detected after 12 weeks of initializing interferon treatment, at the end of
treatment, and 24 week and 1 year follow up after the end of the treatment. At the end of the treat-
ment course, patients who were found to have positive PCR test for HCV RNA in PBMCs were
subdivided into two groups, one group continues to receive IFN therapy while the other group
stops. The HCV RNA in PBMCs and serum was detected by RT-PCR using the Amplicor HCV
2.0 assay.
Results: All patients had negative serum PCR test for HCV RNA at the end of treatment, never-
theless HCV RNA was detected in PBMCs of approximately 32% of these patients. Patients who
tested positively for HCV RNA in PBMCs at the end of treatment had an overall signiﬁcantly
318 A.F.F. Hanno et al.higher relapse rate (50%) when compared with patients who tested negatively for HCV RNA in
both serum and PBMCs at the end of treatment (6%). Patients with positive HCV RNA in their
PBMCs who continue to receive interferon based treatment for further six months had a lower
relapse rate (25%) when compared with similar patients who stopped interferon treatment at the
48th week (75%).
Conclusion: Detection of HCV RNA in PBMCs may be important to assess the virological
response to interferon treatment and to predict relapse after antiviral therapy and may be taken
as a reference to formulate the duration of antiviral therapy in chronic hepatitis C.
ª 2013 Alexandria University Faculty of Medicine. Production and hosting by Elsevier B.V. All rights
reserved.1. Introduction
The resolution of hepatitis C, evidenced by normalization of
liver function and disappearance of hepatitis C virus RNA
from serum as determined by conventional laboratory assays,
reﬂects virus eradication. But in interferon treated patients the
HCV RNA in serum sometimes could not show the virus in
cells.1
Although hepatitis C is mainly hepatotropic, some studies
suggest that hepatitis C virus (HCV) infects peripheral blood
mononuclear cells (PBMCs), using them as a reservoir, which
might contribute to the development of resistance to
treatment.2
Several factors have been found to inﬂuence and predict the
response of chronic HCV patients to interferon therapy, such
as virus genotype,3,4 HCV RNA contents in serum,5 HCV spe-
ciﬁc cellular immunities after treatment,6 state of liver disease,
baseline body weight, age, sex, and race.7–9
Overall, the data accumulated in recent years highlight not
only the need for development and implementation of more
sensitive HCV RNA diagnostic assays but also the importance
of screening both serum and peripheral immune cells for HCV
RNA.10
The aim of the work was to study hepatitis virus C (HCV)
RNA in peripheral blood mononuclear cells (PBMCs) of
patients with HCV infection, and explore the relationship
between the HCV RNA in the PBMCs and response to
interferon (IFN) therapy.
2. Patients and methods
Twenty-ﬁve patients with chronic viral hepatitis C were
selected from outpatient clinic and inpatient ward of tropical
medicine department, Main University Hospital, Alexandria
University during 1/7/2010–1/9/2010. The patients were 17
males and 8 females and range of age was from 38 to 47 years
old (Table 1). All patients gave informed consent to participate
in the study, and the ethics committee approved the protocol.
All patients were subjected to thorough history taking and
clinical examination, routine laboratory investigations includ-
ing CBC, urine, stool and liver function tests.
The diagnosis and inclusion were based on (1) the positivity
of anti-HCV in serum for more than six months before starting
interferon based treatment. (2) The HCV-RNA in serum was
positive before starting interferon treatment. (3) All patients
showed initial response to interferon treatment at the 12th
week. Exclusion criteria included evidence for hepatitis B virusinfection, the presence of any systemic illness other than
chronic hepatitis C, the history of previous use of antiviral
medicine or immunomodulator, the presence of known factors
that might interfere with the response to interferon and lastly
patients who had breakthrough or were found to be non
responders at the end of treatment.
All patients were proved to be eligible candidates for inter-
feron based therapy for chronic hepatitis C according to the
criteria adopted by the National project for treatment of
HCV sponsored by the ministry of Health and all were given
treatment of pegylated interferon alpha 2a (peg IFNa2a) and
ribavirin for 48 weeks without serious side effects. Peg IFN
was given subcutaneously at a dose of 180 lg/week together
with ribavirin 1000–1200 mg daily, 1000 mg for those who
weigh 675 kg and 1200 mg for those who weigh >75 kg.
At the end of the treatment course, patients who were
found to have positive PCR test for HCV RNA in PBMCs
were subdivided into two groups, one group included patients
who were willing and capable to extend interferon based treat-
ment for further six months while the other group included
patients who were unwilling or incapable to receive interferon
treatment after the 48th week.
The HCV RNA in PBMCs and serum was detected after
12 weeks of initializing interferon treatment, after 6 and
9 months of treatment, at the end of treatment, and 24 week
and 1 year follow up after the end of the treatment. The
HCV RNA in PBMC and serum was detected by RT-PCR
using the Amplicor HCV 2.0 assay (Roche Diagnostics).
Detection of HCV RNA in PBMCs depended on Trizol extrac-
tion of RNA. Trizol reagent is ready-to-use reagent for the iso-
lation of total RNA from cells and tissues. The reagent, a
mono-phasic solution of phenol and guanidine isothiocyanate,
is an improvement to the single-step RNA isolation method.
During sample homogenization or lysis, Trizol reagent main-
tains the integrity of the RNA while disrupting cells and dis-
solving cell components. Addition of chloroform followed by
centrifugation, separates the solution into aqueous phase and
an organic phase. RNA remains exclusively in the aqueous
phase. After transfer of the aqueous phase, the RNA is
recovered by precipitation with isopropyl alcohol.3. Results
All patients enrolled in this study showed early viral response
to interferon therapy at week 12. Nineteen of them showed
complete early viral response (Undetectable HCV RNA in
serum), while six showed partial early viral response (HCV
Table 1 Patients’ characteristics.
Age Range: 38–47 y Mean: 42 ± 2.8 y
Sex Males: 17 Females: 8
BMI Mean: 25.2 ± 2.2
AST Mean: 48.24 ± 27.45 IU/L
ALT Mean: 74.88 ± 50.28 IU/L
Viral load (PCR quantitative) Mean: 590,470 ± 748,642 IU/ml
Liver biopsy F2: 22 patients F3: 3 patients
Table 2 The results of HCV-RNA in serum and PBMC after treatment with peg interferon based therapy at weeks 12 and 48.
Group HCV-RNA
in PBMC at
12th week
HCV-RNA
in serum at
12th week
HCV-RNA
in PBMC at
48th week
HCV-RNA
in serum at
48th week
Negative Positive Negative Positive Negative Positive Negative Positive
n= 25 9 (36%) 16 (64%) 19 (76%) 6 (24%) 17 (68%) 8 (32%) 25 (100%) 0 (0%)
Table 3 Comparison between SVR rate in patients positive and negative for HCV RNA at the end of treatment.
SVR rate at 96th week
Patients negative for HCV RNA at both serum and PBMCs at the end of treatment (n= 17) 16/17 (94%)
Patients negative for HCV RNA at the serum but positive in PBMCs at the end of treatment (n= 8) 4/8 (50%)
Chi-square test (Fisher’s exact test) P= 0.0224 signiﬁcant
HCV RNA in peripheral blood mononuclear cells (PBMCs) 319RNA in serum remained detectable but decrease by >2 logs).
Only nine patients were found to have negative PCR test for
HCV RNA in PBMCs after 12 weeks of treatment (Table 2).
The genotype of the virus in all of the patients was genotype 4.
After completion of the treatment (after 48 weeks), all
patients showed normalization of ALT and negative testing
for HCV RNA in serum, while eight of them (32%) showed
positive PCR test for HCV RNA in PBMCs.
Patients with chronic hepatitis C who had detectable HCV
RNA in their PBMCs were divided into two groups (four
patients each). One group was treated with interferon based
therapy for further six months; the other group was only pro-
vided conservative treatment because they were unwilling to
continue interferon treatment owing to ﬁnancial reasons or
for occurrence of intolerable side effects mainly depression.
HCV RNA in PBMCs of three out of the four patients who
continue to receive IFN based therapy becomes undetectableTable 4 The results of negative rate of HCV-RNA in serum and PB
RNA in PBMCs at the end of treatment.
HCV-RNA in PBMC
Negative
Patients who continue to receive Interferon
based therapy (n= 4)
3 (75%)
Patients who received conservative
treatment (n= 4)
1 (25%)
Total 4
Chi-square test (Fisher’s exact test) P= 0.24 not signiﬁcaafter six months by the end of week 72 (Table 4) and PCR test-
ing for HCV RNA in both serum and PBMC after further six
months by the end of week 96 proved also to be negative in
these three patients (Table 5). On the other hand, three
patients from those who received conservative treatment still
had positive HCV RNA in their PBMCs, while only one
patient had undetectable HCV RNA in PBMC after six
months. Moreover, these three patients relapsed after six
months of discontinuation of treatment with positive PCR
testing for HCV RNA in both serum and PBMCs.
Most of the patients (94%) who tested negatively for HCV
RNA in both serum and PBMCs at the end of treatment at
48th week were found to have sustained viral response
(SVR) when PCR testing for HCV RNA in the serum proved
negative after one year of treatment cessation.
Patients with positive HCV RNA in their PBMCs at the
end of the treatment course had a signiﬁcantly lower SVR rateMC after 72 weeks of treatment for patients with positive HCV
at 72nd week HCV-RNA in serum at 72nd week
Positive Negative Positive
1 (25%) 4 (100%) 0 (0%)
3 (75%) 1 (25%) 3 (75%)
4 5 3
nt P= 0.07 not signiﬁcant
Table 5 The results of negative rate of HCV-RNA in serum and PBMC at 96th week for patients with positive HCV RNA in PBMCs
at the end of treatment.
HCV-RNA in PBMC at 96th week HCV-RNA in serum at 96th week
Negative Positive Negative Positive
Patients who continue to receive Interferon based
therapy (n= 4)
3 (75%) 1 (25%) 3 (75%) 1 (25%)
Patients who received conservative treatment
(n= 4)
1 (25%) 3 (75%) 1 (25%) 3 (75%)
Total 4 4 4 4
Chi-square test (Fisher’s exact test) P= 0.24 not signiﬁcant P= 0.24 not signiﬁcant
Table 6 The results of SVR rate and relapse rate in different groups of patients at 72nd and 96th weeks.
SVR Relapse rate
72nd week 96th week 72nd week 96th week
All patients together (n = 25) 22/25 (88%) 21/25 (84%) 3/25 (12%) 4/25 (16%)
Patients negative for HCV RNA at both
serum and PBMCs at the end of treatment
(n = 17)
16/17 (94%) 16/17 (94%) 1/17 (6%) 1/17 (6%)
Patients negative for HCV RNA at the
serum but positive in PBMCs at the end of
treatment (n = 8)
5/8 (63%) 4/8 (50%) 3/8 (37%) 4/8 (50%)
Patients who continue to receive
Interferon based therapy (n= 4)
4/4 (100%) 3/4 (75%) 0/4 (0%) 1/4 (25%)
Patients who received conservative
treatment (n= 4)
1/4 (25%) 1/4 (25%) 3/4 (75%) 3/4 (75%)
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RNA in their PBMCs (Tables 3 and 6). Consequently, higher
relapse rates (50%) of patients who tested positively for HCV
RNA in PBMCs were found compared to those with negative
HCV RNA in their PBMCs (6%) at the end of treatment.
Moreover, those patients with positive HCV RNA in their
PBMCs at the end of the treatment course who continue to
receive IFN treatment for further six months had a higher
SVR rate (75%) and a lower relapse rate (25%) when com-
pared with those who received conservative treatment (Tables
5 and 6). Although there is a big difference in the SVR rates
and relapse rates between patients who continue to receive
IFN treatment and those who received conservative treatment,
this difference was not found to be statistically signiﬁcant
which may be attributed to the small number of the sample.
4. Discussion
Although hepatocytes are considered to be primary targets of
HCV, clinical and experimental evidence strongly indicates
that the virus also invades and replicates in cells of other
organs, particularly the immune system.11,12
In this study, all patients were found to have negative PCR
testing for HCV RNA in their sera at the end of the course of
interferon based treatment. At the same time, HCV RNA was
still detected in freshly isolated peripheral blood mononuclear
cells of approximately 32% of these patients. This ﬁnding is in
accordance with the results reported by Cavalheiro2 et al. who
postulated that the absence of HCV in the serum of patients
with chronic hepatitis C by the end of treatment does not meanthat there is no circulating virus. HCV in mononuclear cells
may be an indicator of the persisting infection. Gallegos-
Orozco et al.13 found that HCV RNA was detected in PBMCs
of 20% of individuals with clinical SVR. He postulated that
viral persistence and, speciﬁcally, the presence of HCV RNA
in PBMCs may lead to HCV reactivation under special circum-
stances, such as immuno suppression.
In agreement to the results of the present study, Zayed
et al. reported the presence of detectable HCV RNA in the
PBMC of 27% of patients despite the clearance of serum
HCV RNA. During follow-up, 80% of the patients who
became serum HCV positive 6 months after the end of treat-
ment had a detectable level of HCV RNA in PBMC at the
end of treatment. They concluded that the absence of HCV
in the serum of patients by the end of treatment does not
exclude future viremia. The patient might still be a source
of infection to others and they were recommended to testing
for HCV in PBMC to detect lack of response to treatment
and persisting infection.14
Similarly, Gong et al. reported that HCV is capable of
infecting and replicating in PBMCs. HCV plus strand RNA
as well as minus strand RNA and HCVNS5 protein were
found in PBMCs of 62.9%, 40.0% and 85.0% of chronic hep-
atitis C patients respectively. The patients with minus strand
HCV RNA in PBMCs showed a signiﬁcantly lower 6-month
sustained response to IFN, suggesting that minus-strand (a
viral replicative form) HCV RNA in PBMCs may be one of
the factors inﬂuencing response to IFN therapy.15
Patients included in the present study showed an overall
high SVR rate (84%) which may be attributed to the proper
HCV RNA in peripheral blood mononuclear cells (PBMCs) 321selection of patients (young age, low viremia, no obesity and
early stage of liver disease) and the standard of care provided
for them. Moreover, an even higher SVR rate (94%) was
noticed in patients who tested negatively for HCV RNA in
both serum and PBMCs at the end of treatment at the 48th
week. This may give us a clue to the role played by the persis-
tence of HCV RNA in PBMC on the ﬁnal outcome of the
treatment. On the other hand, those patients who tested posi-
tively for HCV RNA in PBMCs at the end of treatment had a
lower SVR rate (50%) when compared with patients who
cleared the HCV RNA from their PBMCs. In other words,
patients who tested positively for HCV RNA in PBMCs at
the end of treatment had a higher relapse rate (50%) when
compared with patients who tested negatively for HCV RNA
in both serum and PBMCs at the end of treatment (6%).
Relapse following end of treatment of antiviral therapy is
common. Some authors suggested that patients ‘‘cured’’ after
antiviral treatment with persistent viral response may have
occult HCV infection in the liver or PBMCs as they demon-
strated that HCV can ﬁnish replication within PBMCs.16 How-
ever, this concept is not generally accepted as Halfon and
coworkers17 questioned the existence of occult HCV infection
as they have not detected HCV RNA in the peripheral blood
mononuclear cells (PBMCs) of patients with cryptogenic liver
diseases. However, negativity for HCV RNA in PBMCs does
not exclude the existence of occult HCV infection because
the ‘‘gold standard’’ method to identify this occult infection
is by the detection of viral RNA in liver cells. Moreover, when
negative data are reported, the sensitivity of the assay is critical
to ensure that the lack of HCV RNA detection is not due to
the low sensitivity of the technique used.18,19 Other researchers
postulated that contamination or passive adsorption by circu-
lating virus could be the reason for the detection of HCV-
RNA in PBMC preparations of chronically infected patients.20
Thus HCV in PBMCs may be one of the causes of relapse
after antiviral therapy. In certain scenarios including immuno-
suppression, immunomodulatory therapy or co-infection,
instead of eliciting desirable T cell responses in the host, persis-
tent replicating HCV could represent a potential source for
virus reactivation, as it has been shown in other viruses,
including hepatitis B virus10 and human herpesvirus 6.21
In the present study, follow up for patients showed that
patients with positive HCV RNA in their PBMCs who con-
tinue to receive interferon based treatment for further six
months had a lower relapse rate when compared with patients
who stopped interferon treatment at the 48th week. Xu et al.1
reported that viral relapse was due to nonclearance of virus in
cells including hepatocytes and PBMCs although complete
response was acquired at the end of treatment. HCV RNA
level in serum did not reﬂect virus situation in cells at the
end of IFN treatment of chronic hepatitis C. Moreover,
although patients showed complete response at 12 weeks, it
did not signify that the patients would acquire sustained viral
response.
In conclusion, detection of HCV RNA in PBMCs may be
important to assess the virological response to interferon treat-
ment and to predict relapse after antiviral therapy. Perhaps
nonclearance of HCV RNA in PBMCs may be a predictor
of unsatisfactory response to antiviral therapy and is a refer-
ence to formulate the duration of antiviral therapy in chronic
hepatitis C. In this situation prolongation of the interferontreatment may be a recommended strategy, a hypothesis that
is in need for further veriﬁcation.Conﬂict of interest
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